VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
AKBAAkebia Therapeutics, Inc.
$1.07$287M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAKBAEarnings History

AKBA logoAkebia Therapeutics, Inc. (AKBA) Earnings History

Net Loss

14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$21M
● Net Loss
TTM EPS (Diluted)
$-0.08
Per share, diluted
YoY EPS Growth
+93.7%
Excellent
Net Margin
-2.3%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin9.9%
Gross Margin83.3%
Return on Equity-16.4%
Return on Assets-1.8%
Record Annual Net Income-$5MFY2025
Record Quarterly EPS$0.25Q4 2017
Consecutive Profitable Years0years
Q1 2026
Net Income-$9M
EPS (Diluted)$-0.03
YoY Growth+93.7%Excellent
QoQ Growth+26.1%Excellent

Loading earnings history...

Akebia Therapeutics, Inc. (AKBA) Earnings Overview

As of June 22, 2026, Akebia Therapeutics, Inc. (AKBA) reported trailing twelve-month net income of -$21M, reflecting +93.7% year-over-year growth. The company earned $-0.08 per diluted share over the past four quarters, with a net profit margin of -2.3%.

Looking at the long-term picture, AKBA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2025, representing a new all-time high.

Akebia Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including FOLD (-$27M net income, -4.3% margin), PTGX (-$115M net income, -282.8% margin), CYCN (-$5M net income, -170.1% margin), AKBA has outperformed on profitability metrics. Compare AKBA vs FOLD →

AKBA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
AKBA logoAKBACurrent
-$21M$-0.08-2.3%-16.4%+93.7%—
FOLD logoFOLD
-$27M$-0.09-4.3%-11.6%+51.2%
PTGX logoPTGX
-$115M$-1.63-282.8%-20.2%-148.5%
CYCN logoCYCN
-$5M$-1.25-170.1%-39.3%+9.9%
ANIP logoANIP
$90M$4.168.9%16.2%+419.2%
HALO logoHALO
$349M$2.8422.7%153.6%-25.4%
Best in group
Lowest in group

AKBA Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$5M+92.3%$23M$-0.02-2.3%9.9%
2024-$69M-33.7%-$50M$-0.33-43.3%-31.5%
2023-$52M+44.9%-$46M$-0.28-26.7%-23.8%
2022-$94M+66.6%-$81M$-0.58-32.2%-27.6%
2021-$282M+26.7%-$265M$-1.48-133.3%-125.0%
2020-$385M-37.6%-$378M$-2.53-130.6%-128.2%
2019-$280M-62.7%-$286M$-2.36-83.5%-85.5%
2018-$172M-123.5%-$178M$-1.47-82.7%-85.8%
2017-$77M+43.3%-$80M$-1.77-43.2%-44.9%
2016-$136M-123.6%-$136M$-3.60-8843.5%-8889.9%
2015-$61M-63.9%-$62M$-2.29--
2014-$37M-181.3%-$38M$-2.40--
2013-$13M-60.7%-$16M$-0.68--
2012-$8M--$9M$-0.81--

Download Data

Export AKBA earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AKBA — Frequently Asked Questions

Quick answers to the most common questions about buying AKBA stock.

What is AKBA earnings per share (EPS)?

AKBA trailing twelve-month (TTM) diluted EPS is $-0.08, reflecting +93.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Akebia Therapeutics, Inc.'s net income?

Akebia Therapeutics, Inc. (AKBA) trailing twelve-month net income is $-21M as of 2025. Earnings grew +93.7% year-over-year.

Is AKBA profitable?

AKBA is not currently profitable on a TTM basis, reporting a net loss of $-21M. Net margin is -2.3%. Investors should monitor for a return to profitability.

What is AKBA's earnings growth rate?

AKBA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are AKBA's profit margins?

Akebia Therapeutics, Inc. net profit margin is -2.3%, operating margin is +9.9%, and gross margin is +83.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -16.4%.

Is AKBA growing earnings?

Yes, AKBA earnings are accelerating — EPS growth of +93.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-21M. Earnings momentum is strengthening.

What was AKBA's best earnings year?

Akebia Therapeutics, Inc.'s highest annual net income on record is $-5M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were AKBA's earnings last quarter?

AKBA's most recent reported quarter was Q1 2026. Net income was $-9M with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.

AKBA Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view